NCT07179770 - Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

October 1, 2027

Conditions

Metastatic Clear Cell Renal Cell Carcinoma

Interventions

DRUG

Belzutifan

120 mg orally daily for 28 days

DRUG

89Zr-DFO-girentuximab

10 mg single slow intravenous (IV) administration

DEVICE

89Zr-DFO-girentuximab PET

89Zr-DFO-Girentuximab PET before and after 4 weeks of treatment with standard-of-care (SOC) belzutifan.

Trial Locations (1)

RECRUITING

NYU Langone Health, New York

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

NYU Langone Health

OTHER